You can buy or sell Teligent and other stocks, options, ETFs, and crypto commission-free!
Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. Read More The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.
Buena, New Jersey
52 Week High
52 Week Low
Teligent Inc. Stock Quote (U.S.: Nasdaq)
Shares of Teligent, Inc. shot up 12% in premarket trade Thursday after the company announced the U.S. Food and Drug Administration had approved the company's abbreviated new drug application for a generic 0.05% solution of clobetasol propionate ointment, a topical steroid used to treat skin irritation. The company said it plans to launch the product sometime this month and that the total addressable market for the product is approximately $70.5 million, according to data from November from IQVIA . Shares of...
Seeking AlphaMar 18
Teligent, Inc. (TLGT) CEO Jason Grenfell-Gardner on Q4 2018 Results - Earnings Call Transcript
Teligent, Inc. (NASDAQ:TLGT) Q4 2018 Earnings Conference Call March 18, 2019 8:00 AM ET Company Participants Jason Grenfell-Gardner - President and CEO Damian Finio - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Elliot Wilbur - Raymond James Operator Good day, ladies and gentlemen, and welcome to the Teligent, Incorporated Fourth Quarter 2018 Results Conference Call. [Operator Instructions] As a reminder, this conference call maybe recorded. Except for historical facts, the s...
Seeking AlphaMar 18
Teligent down 14% on Q4 results
Teligent (TLGT) Q4 results: Revenues: $16.8M (+13.5%). Net Loss: ($14.4M) (-136.1%); Loss Per Share: ($0.27) (-145.5%); Non-GAAP Loss Per Share: ($0.18) (200.0%); Non-GAAP Net Loss: ($9.8M). 2019 Guidance: Revenue: double digit top line percentage growth with revenues in excess of $72.5M....
-$0.03 per share
-$0.18 per share